Novavax, Inc.
HealthcareNASDAQ:NVAX · NASDAQ Global Select
-$0.15 today
Vol 2.59M · Avg 4.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-344.7%
avg 513.6%
ROIC
78.0%
avg -155.8%
ROA
37.4%
avg -42.2%
Analysis
ROIC is currently the strongest return metric at 78.0% versus its period average of -155.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Charles Jacobs | President, Chief Executive Officer & Director | $1.55M | — | 59 | $19,040.00 | 0.01% |
Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary | $984,255.00 | — | 63 | $101,445.00 | 0.06% |
Elaine O'Hara | Executive Vice President & Chief Strategy Officer | $947,011.00 | — | 58 | $157,071.00 | 0.10% |
James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | $884,281.00 | — | 60 | $136,503.00 | 0.08% |
Richard Crowley | Executive Vice President & Chief Operating Officer | — | — | 69 | $28,490.00 | 0.02% |
Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | — | — | 55 | — | — |
Erika S. Trahan | Associate Director of Investor & Public Relations | — | — | — | — | — |
Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | — | — | — | — | — |
Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | — | — | 63 | — | — |
Luis Sanay | Vice President of Investor Relations | — | — | — | — | — |
Robert Walker | EVice President and Head of Research & Development | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +18.0% | +17.1% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.0% over three years. Forward estimates point to Revenue at +17.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
CureVac N.V.
CVAC
$1.05B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Upstream Bio, Inc.
UPB
$331.96M
Who manages NVAX?
Novavax, Inc. (NVAX) lists 11 active executives. The top listed executive is John Charles Jacobs, President, Chief Executive Officer & Director.
Are NVAX insiders buying or selling?
Recent insider activity shows net buying of $34.46M.
Explore More
Continue the stock analysis
Jump to another research area for this company.